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ABSTRACT 
 
miRNAs are short single-stranded non-coding RNAs which regulate gene expression at 
the post-transcriptional level in many biological processes, including proliferation, 
apoptosis and differentiation. A number of studies have shown the importance of 
miRNAs in carcinogenesis and accumulating evidence supports their role as diagnostic 
and prognostic biomarkers in human cancers. Moreover, dysregulation of miRNA 
processing factors, which are needed for miRNA maturation, have been recently shown 
to play an important role in tumor initiation and progression and to have a prognostic 
potential in different types of cancer. Despite all the achievements, our knowledge of 
the biological role of miRNAs and miRNA processing pathway in tumor development 
and progression is still in its infancy.  
 
The general purpose of this thesis was to improve our understanding of the clinical and 
functional implications of miRNA deregulation in human cancer.  
 
In paper I, we reported frequent deregulation of miRNA expression in lymph node 
metastases of malignant melanoma and melanoma cell lines as compared to normal 
melanocytes and showed its association to BRAF and NRAS mutational status. 
Moreover, we identified a two-miRNA signature that could predict survival in 
metastatic melanoma patients. 
In paper II, we performed genome-wide miRNA expression profiling of adrenocortical 
tumors and identified distinct miRNA expression patterns in adrenocortical carcinomas 
(ACC) compared to adenomas and normal adrenal cortices. Over-expression of miR-
483-3p/-5p and down-regulation of miR-195 and miR-497 were the most common 
features of ACC. We also elucidated the functional consequences of deregulation of 
these 4 miRNAs on cell proliferation and apoptosis in ACC cells and, in addition, we 
demonstrated the potential involvement of the pro-apoptotic factor PUMA (a target of 
miR-483-3p) in adrenocortical tumors. Moreover, we found novel miRNAs associated 
with short survival in ACC. 
In paper III, we evaluated the expression and the potential role of the main 
components of the miRNA machinery in adrenocortical tumors. We observed frequent 
over-expression of TRBP2 in ACC and found that TRBP2 mRNA expression level is a 
reliable predictor of carcinoma among adrenocortical tumors. These data suggest that 
TRBP2 may be a novel and sensitive biomarker for adrenocortical tumors. 
Functionally, we unraveled the potential oncogenic role of TRBP2 in ACC and 
identified some of the molecular mechanisms involved in the regulation of TRBP2 
expression in this tumor type. 
In paper IV, we analyzed the expression of miRNAs and miRNA machinery factors in 
diffuse large B-cell lymphoma (DLBCL). We identified miRNA signatures that could 
discriminate DLBCL tumors from non-neoplastic tissue and found subsets of miRNAs 
able to classify DLBCL sub-types. Moreover, we showed dysregulation of miRNA 
machinery factors in DLBCL and demonstrated that it could influence miRNA 
processing. We also showed, similarly to our observations in ACC, that deregulation of 
TRBP2 expression could affect cell proliferation and cell death in lymphoma cell lines, 
suggesting its potential oncogenic role in DLBCL development. 
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1 INTRODUCTION 
 
The central dogma of molecular biology proposed by Francis Crick in 1958 (Crick, 
1958) is based on the assumption that genes are transcribed to RNA and subsequently 
translated into proteins which play a major role in most of the regulatory molecular 
pathways from unicellular to complex organisms. However, in the last decade, the 
development of high-throughput sequencing platforms has led the scientific community 
to the discovery that non-protein-coding RNAs (ncRNAs) represent over 90% of the 
human genome (Bertone et al., 2004; Birney et al., 2007). At the present, many classes 
of ncRNAs have been identified and, although, the function is not yet completely 
uncovered their role in regulatory cellular pathways is well recognized. Non-coding 
RNAs can be classified as small non-coding RNAs (18-200nt) which include e.g. 
microRNAs (miRNAs), small interfering RNAs (siRNAs), piwi-interacting RNAs 
(piRNAs), small vault RNAs (svRNAs) small nuclear RNAs (snRNAs), vault RNAs 
(vtRNAs), small nucleolar RNAs (snoRNAs) (Aravin et al., 2006; Bartel, 2004; Kawaji 
et al., 2008) or long non-coding RNAs (200nt-100kb) including among others long 
intergenic ncRNAs (such as HOTAIR) and transcribed ultraconserved regions (tUCRS) 
(Calin et al., 2007; Rinn et al., 2007). 
 
In this thesis, we will focus on miRNAs, which probably represent the most studied 
class of ncRNAs, with special emphasis on their role in tumor development and 
progression and the clinical impact on diagnosis, prognosis and treatment of human 
malignancies.   
 
 
1.1 MiRNA discovery 
 
miRNAs are single-stranded RNAs of ~22 nucleotides in length that are generated by 
the RNase-III type enzyme Dicer from endogenous hairpin-shaped transcripts and 
regulate gene expression at the post-transcriptional level (Ambros, 2001; Kim, 2005). 
The first discovery in the miRNA field dates back to 1993, when Victor Ambros and 
collaborators cloned lin-4, a gene involved in C. elegans development regulation, that 
does not encode for any protein but produces a ~22nt long RNA molecule from a 
longer hairpin-shaped RNA precursor (Lee et al., 1993; Wightman et al., 1993). 
Further, they and others discovered that the lin-4 RNA acted as an antisense 
translational repressor and could regulate expression of the lin-14 gene binding to 
complementary sequences in its 3'untranslated region (UTR) (Lee et al., 1993; 
Wightman et al., 1993). Lin-4 was believed to be a unique species until year 2000 when 
a new small RNA, let-7, was reported in C. elegans (Reinhart et al., 2000). 
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Interestingly, let-7 was also found to be highly conserved in a variety of organisms 
(Pasquinelli et al., 2000). Since then a large number of similar small RNA sequences, 
for the first time termed as miRNAs in 2001, were discovered in a wide range of 
organism from nematodes to vertebrates, plants and viruses. miRNAs are now 
recognized as a conserved class of small non-coding RNAs which are believed to 
regulate more than 60% of the human protein-coding genes (Friedman et al., 2009) and 
are involved in many biological processes such as development, proliferation, 
differentiation, antiviral defense, and tumorigenesis (Ambros, 2001; Bartel, 2004; 
Bennasser et al., 2004; He and Hannon, 2004; Kim, 2005). Until November 2011, 
nearly 1500 human mature miRNAs have been annotated in the miRBase database 
Release 18.0 (http://www.mirbase.org/; Griffiths-Jones, 2004). 
 
 
1.2 MiRNA biogenesis and function 
 
The majority of known miRNAs are located within introns or exons of protein coding 
or noncoding genes. Nearly 50% derive from non-coding RNA transcripts while only 
10% have been found to be transcribed from exons of either protein-coding or non-
coding transcription units. The other miRNAs are located within introns of protein-
coding genes and are often co-transcribed together with their host transcripts. 
Approximately 25-30% of intronic miRNAs are instead transcribed from independent 
promoters. A second group of miRNAs are located in intergenic regions and derive 
from independent transcription units (Corcoran et al., 2009; Rodriguez et al., 2004). 
Moreover, over 40% of human miRNAs are found as clusters and are co-transcribed 
from a single polycistronic transcription unit (Altuvia et al., 2005). Interestingly, in 
some cases, miRNA can be transcribed from two different genes (e.g. miR-29b-1 from 
chromosome 7 and miR-29b-2 from chromosome 1. Both of these miRNAs have the 
same mature sequence (Garzon et al., 2009).  
 
1.2.1 Biogenesis: transcription and miRNA maturation 
miRNA biogenesis is a complex multistep process. In the canonical pathway, miRNAs 
are transcribed as long primary transcripts (pri-miRNA) mostly by RNA polymerase II 
(Lee et al., 2004), although polymerase III is also required for the transcription of a 
subset of miRNAs (Borchert et al., 2006). The pri-miRNAs are several kilobases long 
transcripts characterized by a stem-loop structure and are cleaved within the nucleus by 
the RNase III-type enzyme Drosha, and its co-factor DGCR8 (DiGeorge Syndrome 
Critical Region 8), to release the precursor miRNAs (Pre-miRNA) (Lee et al., 2003). 
The 60-70nt long hairpin-like pre-miRNAs are exported to the cytoplasm through 
exportin 5 (XPO5) (Bohnsack et al., 2004) and further processed by Dicer (another 
RNase III-type enzyme), together with the co-factors TRBP (TAR RNA-binding 
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protein) and PACT (protein activator of PKR), to form a ~22nt asymmetric miRNA 
duplex (Hutvagner et al., 2001; Ketting et al., 2001; Lee et al., 2006). The miRNA 
duplex is a short-lived intermediate which is loaded into the miRNA-induced silencing 
complex (miRISC), where argonaute (Ago) proteins are the core effector components 
(Filipowicz et al., 2005). In the miRISC complex one strand of the duplex becomes the 
mature miRNAs while the other strand is degraded depending on the thermodynamic 
stability of the two ends of the duplex (Khvorova et al., 2003; Schwarz et al., 2003). 
 
1.2.1.1 Alternative pathways and regulatory mechanisms in miRNA biogenesis 
Although the miRNA processing pathway was previously thought to be a linear and 
universal process, alternative biogenesis pathways have recently been described. 
Mirtrons are short introns that after splicing resemble the pre-miRNA hairpin structure 
and enter the miRNA biogenesis process and bypass the Drosha-mediated cleavage 
(Berezikov et al., 2007). Another non-canonical biogenesis pathway is represented by 
Dicer-independent miRNAs: pre-miRNA is directly incorporated in the Ago complexes 
where the miRNA maturation is mediated by Ago cleavage activity producing an 
intermediate product which is further processed by endo- or exonucleases (Cheloufi et 
al., 2010). In addition, post-transcriptional regulation processes that generate mature 
miRNA variants (or isomiRs) have been reported. The pri-miRNA transcripts can be 
altered through nuclear RNA editing by the enzyme ADAR (adenosine deaminase 
acting on RNA) which catalyzes the conversion from adenosine (A) to inosine (I). 
Changing the sequence of pri-miRNAs, the RNA editing may affect base-pairing and 
structural properties of the primary transcripts and can influence their further 
processing as well as the function of the mature miRNA (altering target specificity 
through sequence changing in the seed region) (Blow et al., 2006; Kawahara et al., 
2008). For example, the editing of miR-142 modifies the secondary structure of the pri-
miRNA and prevents the cleavage by Drosha, leading to degradation of pri-miR-142 by 
the ribonuclease TUDOR-SN (Tudor staphylococcal nuclease) (Yang et al., 2006b). 
RNA editing can also occur on the pre-miR species and can prevent Dicer processing. 
This results in an accumulation of the pre-miR affecting the expression of the mature 
form (Kawahara et al., 2008). The isomer variability can also be generated by a shift of 
Dicer or Drosha cleavage position at the 5' or 3'-end or by nucleotide additions at the 3'-
end. Modifications at the 3'-end are common post-transcriptional events that are 
phylogenetically conserved and are mediated by the activity of multiple 
nucleotidyltransferases. These modifications result predominantly from adenylation or 
uridylation although addition of guanine has also been observed. Uridylation, at least in 
part, seems to be catalyzed by ZCCHC11 (zinc finger CCHC domain containing 11), 
ZCCHC6 (zinc finger CCHC domain containing 11) and TUT1 (terminal uridylyl 
transferase 1) nucleotidyltransferase and primarily take place on the pre-miRNA and 
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affects the processing by Dicer. Adenylation is mediated by PAPD4 and PAPD5 (PAP 
associated domain containing 4 or 5) enzymes after Dicer cleavage. All these 
modifications are related with reduced miRNA efficiency in target recognition 
(Burroughs et al., 2010; Morin et al., 2008; Wyman et al., 2011). 
 
1.2.2 Function: target recognition and regulation 
The mature miRNA guides the miRISC to specifically recognize and regulate particular 
mRNA targets. The miRNA binding sites are generally present in the 3’UTR of the 
target transcripts: location, number and proximity of miRNA binding sites along an 
mRNA target contribute to the miRNA-mediated gene regulation (Brennecke et al., 
2005; Grimson et al., 2007; Lewis et al., 2005; Nielsen et al., 2007). The most stringent 
requirement for miRNA-mRNA pairing is the perfect interaction of miRNA 
nucleotides 2-7 to the 5' end, representing the seed region. Pairing of the 3' region (3'-
supplementary sites and 3'-compensatory sites) of the miRNA can enhance target 
recognition and in some cases can even compensate for a mismatch to the seed region 
(Bartel, 2009). Recently, ''centered sites'' have been described to indicate miRNA target 
sites lacking of both perfect seed pairing and 3'-compensatory sites but instead 
presenting 11-12 contiguous perfect pairs to the center of the miRNA (Shin et al., 
2010). The degree of miRNA-mRNA complementarity will define the outcome of this 
interaction. Perfect base pairing, either in the coding region or in the 3'UTR of the 
target, will lead to miRNA-dependent cleavage of mRNA-target (Meister et al., 2004; 
Yekta et al., 2004). An imperfect miRNA-mRNA target pairing will cause repression of 
translation and/or mRNA deadenylation, followed by destabilization of the targets 
(Pillai et al., 2007).  
 
As previously described, post-transcriptional modifications resulting in changes of the 
mature miRNA sequence can influence the miRNA-mRNA target interaction and 
regulation. In addition, SNPs in the 3'UTR of the target genes might modify binding 
sites altering miRNA function. Single nucleotide polymorphism has been observed 
within the binding site recognized by let-7 in the 3'UTR of KRAS and was associated 
with an increased risk of non-small cell lung cancer (Chin et al., 2008). Recently, 
Sandberg et al. showed that highly proliferating cells express mRNAs with shorter 
3'UTRs. This mechanism leads to a reduction of miRNA binding sites in the 3'UTR and 
consequently proliferating cells become resistant to miRNA-dependent repression 
(Sandberg et al., 2008). Alternatively, mRNA binding factors, under certain conditions 
(e.g. cellular stress), may associate with miRNA binding sites in the 3'UTR of specific 
mRNA target and affect miRNA-guided gene silencing (Bhattacharyya et al., 2006; 
Kedde et al., 2007).   
 
   5 
Recently, non-canonical miRNA-mediated mechanisms of mRNA target regulation 
have been proposed. Some miRNAs were shown to bind to the 5'UTR of target genes 
and exceptionally to activate rather than repress gene expression (Lytle et al., 2007; 
Orom et al., 2008). Interestingly, under specific conditions, miRNAs can also switch 
from repression to translational activation of their own targets. Vasudevan et al. 
showed that human Ago2 activates translation of target mRNAs during cell cycle arrest 
caused by serum starvation or contact inhibition while, in proliferating cells, the same 
targets are normally repressed (Vasudevan et al., 2007). Moreover, miRNAs can bind 
to ribonucleoproteins in a RISC-independent manner and interfere with their RNA 
binding properties (decoy activity) (Eiring et al., 2010). Additional studies have shown 
that miRNAs can regulate gene expression also at the transcriptional level by binding 
directly to the DNA (Khraiwesh et al., 2010; Kim et al., 2008) (Figure 1). 
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Figure 1. Biogenesis and function of miRNAs and siRNAs. 
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1.2.3 Not only metazoan miRNAs 
It was generally believed that miRNAs belong to a class of small non-coding RNAs 
regulating gene expression only in metazoans. However, later in 2002, cloning of small 
RNAs revealed the presence of miRNAs also in plants, indicating that miRNAs arose 
early in eukaryotic evolution. Like in metazoans, miRNAs in plants are endogenously 
expressed 20-24nt long non-coding RNAs which derive from hairpin-shaped precursors 
and generally are evolutionary conserved (Reinhart et al., 2002). At present more than 
4000 miRNAs from 52 plant species have been annotated in the miRBase database 
(Griffiths-Jones, 2004). Differences between plant and animal miRNAs are mainly 
related to their biogenesis. In plants, miRNA genes are primarily located in genomic 
regions not associated with protein-coding genes indicating that they are produced from 
their own transcriptional units (Reinhart et al., 2002). Like in metazoans miRNA genes 
are transcribed by RNA polymerase II into long primary transcripts; however, the 
processing of pri-miRNA into an asymmetric miRNA duplex occurs entirely in the 
nucleus and is carried out by a RNaseIII enzyme, DCL1 (DICER-LIKE 1). Two co-
factors, HYL1 (HYPONASTIC LEAVES 1, dsRNA binding protein) and SE 
(SERRATE, C2H2-type zinc finger), are also required for pri-miRNA processing (Han 
et al., 2004; Yang et al., 2006a). Different from animals pri-miRNAs which have a 
~70nt stem-loop structure, in plants the stem-loop structure of pri-miRNA can be 
greatly variable in length and is usually larger than those in animals (>100nt) (Reinhart 
et al., 2002). After DCL-mediated cleavage and HEN1 (ENHANCER 1) methylation 
(Yu et al., 2005), the single stranded miRNA is exported to the cytoplasm and 
incorporated in the RISC complex similarly to metazoan miRNAs. Plant miRNAs 
show a better complementarity to their targets compared to miRNAs in animal and 
generally induce cleavage of the targeted transcript (Reinhart et al., 2002; Rhoades et 
al., 2002) although cases of gene expression regulation via translational repression have 
been reported (Chen, 2004). In plants, miRNAs can regulate a diverse number of 
pathways including development, cell differentiation, hormone signaling and stress 
response (Allen et al., 2005; Reinhart et al., 2002). 
 
Virus-encoded miRNAs (vi-miRNAs) were identified for the first time in Epstein-Barr 
virus (EBV) by Pfeffer and colleagues in 2004 (Pfeffer et al., 2004). Today, more than 
200 virus-encoded miRNAs have been identified (miRBase database Release 18.0; 
Griffiths-Jones, 2004) in DNA viruses and retroviruses but not in RNA viruses. Given 
that miRNA biogenesis is a process that is initiated in the nucleus, it is believed that in 
viruses with RNA genome, which replicate exclusively in the cytoplasm of the infected 
cells, the generation of miRNAs is not available (Pfeffer and Voinnet, 2006). Although 
natural miRNAs encoded by RNA viruses have not yet be identified, a recent study 
showed that, at least at a mechanistic level, the production of mature miRNAs is 
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possible also for Tick-Borne Encephalitis Virus, an ssRNA virus (Rouha et al., 2010). 
However, data showing production of miRNAs in other RNA viruses are not available 
yet. Today, the function of most of the viral miRNAs is still unknown, however it has 
been shown that they can target and regulate the expression of both host genes, which 
may interfere with stages in the viral life cycle, and virally encoded transcripts (Pfeffer 
et al., 2004). The latter mechanism seems to be relevant to regulate the accumulation of 
viral products required during specific phases of infection (Pfeffer and Voinnet, 2006). 
 
1.2.4 siRNAs and miRNAs: similarities and differences  
The RNA interference (RNAi) pathway is an evolutionary conserved mechanism 
among eukaryotes involved in sequence-specific gene silencing. This biological 
process, which was originally observed in plants in the early ‘90s and later in the worm 
C. elegans, is triggered by long double-stranded RNA that either is artificially 
introduced in cells or is naturally generated, such as sense and antisense transcripts, 
transposons or intermediate products of viral replication (Cogoni and Macino, 1999; 
Fire et al., 1998; Ketting et al., 1999; Li et al., 2002; Napoli et al., 1990; Smith et al., 
1990; van der Krol et al., 1990). Although, siRNAs and miRNAs differ in their 
molecular origins, they share many common features in terms of molecular 
characteristics, biogenesis and target recognition modalities. Like miRNAs, the double-
stranded RNA is processed in the cytoplasm by Dicer into ~22nt double-stranded small 
interfering RNAs (siRNAs). However, during miRNA biogenesis each pre-miRNA 
generates a single miRNA duplex, while a multitude of siRNA molecules are produced 
from both strands of each dsRNA precursor (Hamilton and Baulcombe, 1999; Ketting 
et al., 2001; Parrish et al., 2000). Subsequently, siRNAs are incorporated in the RISC 
complex as single-stranded RNAs and can bind to their target with perfect 
complementarity and therefore regulate gene expression by directing cleavage of the 
target mRNAs (Elbashir et al., 2001; Martinez et al., 2002). On the other hand, when 
siRNA pair imperfectly to their targets, they can act as miRNAs and induce 
translational repression rather than mRNA cleavage (Doench et al., 2003) (Figure 1). 
While the miRNA-mediated gene regulation is referred to as heterosilencing (the 
regulated genes are distinct from the gene that the miRNAs originate from), siRNAs 
are defined as cis-acting since they induce the degradation of RNAs from which they 
derive (e.g. transposons or viral RNAs) (Bartel, 2004).  
 
Primarily, it seems that RNA interference functions as a defense mechanism against 
viral infection in flies and plants, although viruses have themselves evolved strategies 
to suppress the RNA-silencing pathway (Baulcombe, 2004; Keene et al., 2004; Li et al., 
2002). However, it is not clear whether RNAi acts as antiviral defense mechanisms also 
in mammalian cells. In these organisms the presence of viral duplexes activates an 
interferon-mediated pathway resulting in non-specific RNA degradation and repression 
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of protein synthesis which will lead to destruction of virus-infected cells by apoptosis 
(Katze et al., 2002). Although, these observations imply that RNAi-mediated antiviral 
response is not needed in mammals, several recent studies indicate that mammalian 
viruses can interact and suppress the cellular RNAi machinery, suggesting that viruses 
infecting mammalian cells are targeted by the RNAi machinery and that RNAi might 
regulate viral replication (Johnson et al., 2004; Li et al., 2004; Sullivan and Ganem, 
2005). Furthermore, virus-derived siRNAs have recently been identified, suggesting 
that viral sequences can be processed by Dicer (Andersson et al., 2005; Lu and Cullen, 
2004). Adenoviral virus-associated RNA I and II are expressed at high levels during 
infection by adenovirus and are responsible of blocking the activation of PKR, which is 
involved in cellular antiviral defense mechanisms. In addition, they can also inhibit the 
RNAi pathway in the infected host cells: the virus-associated RNAs are processed by 
Dicer and the derived siRNAs are incorporated in the RISC. However, at the moment, 
their modality of action is still unclear. It has been proposed that they might act by 
saturating the RNAi machinery preventing to take action against viral coding genes. 
Alternatively, the virus associated-siRNAs might work as miRNAs and silence gene 
expression in the host (Andersson et al., 2005; Lu and Cullen, 2004). 
 
It has been shown that endogenous siRNAs can silence retrotrasposons in plants 
(Hamilton et al., 2002) and more recently natural siRNAs, derived from LINE-1 (Long 
interspersed nuclear element type 1, or L1) retrotrasposons, have been identified in 
cultured mammalian cells (Watanabe et al., 2006). L1 retrotrasposons are highly 
abundant in human comprising approximately 17% of the human genome, and can be 
transcribed from sense and antisense promoters. The resulting bidirectional transcripts 
can be processed to siRNAs that suppress retrotransposition of L1 elements by RNAi 
mechanism (Yang and Kazazian, 2006). Endogenous siRNAs derived from 
transposable elements in mammals have also been identified in fully grown mouse 
oocytes (Watanabe et al., 2006). 
  
In addition, there are evidences showing that the RNAi pathway, beside post-
transcriptional gene regulation, is also involved in gene silencing at the transcriptional 
level. This mechanism, known as siRNA-directed transcriptional silencing (RdTS), was 
initially reported in plants and yeasts where siRNAs can induce specific promoter 
methylation or histone and heterochromatin modifications to repress gene expression 
(Grewal and Moazed, 2003; Mette et al., 2000; Volpe et al., 2002). Later, RdTS was 
also found in mammalian cells, indicating an evolutionary conservation, and was 
shown to involve epigenetic changes, similar to plants and yeast (Morris et al., 2004; 
Ting et al., 2005; Weinberg et al., 2006). Although the processes involved in siRNA-
directed transcriptional silencing in mammals are still poorly understood, different 
possible mechanisms have been proposed. A few studies demonstrated the 
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transcriptional silencing might require the involvement of Argonaute proteins (such as 
AGO1 and AGO2) (Janowski et al., 2006) or alternatively siRNAs might bind to 
single-stranded DNA regions, e.g. transcription start sites, and physically inhibit the 
transcription (Janowski et al., 2005). Recently, it has also been shown that siRNAs bind 
to single-stranded promoter-associated RNAs forming RNA:RNA hybrids which 
function as recognition sites to direct gene silencing complexes (Han et al., 2007). 
 
 
1.3 MiRNA and cancer 
 
Tumor development and progression is generally regarded as a multistep process 
characterized by accumulation of genetic changes over time. Each change contributes 
to the accumulation of specific features that eventually will lead to the malignant 
status. Malignant cancer cells grow in an uncontrolled manner, become resistant to 
programmed cell death (apoptosis) and acquire the ability to invade adjacent tissues 
and to metastasize.  
 
A potential involvement of miRNAs in pathogenesis of cancer was shown for the first 
time in 2002, when Calin and colleagues (Calin et al., 2002) identified two miRNAs, 
miR-15a and miR-16 which are located in chromosomal region 13q14. This genomic 
region is deleted in most cases of chronic lymphocytic leukemia (CLL) and the two 
miRNAs were under-expressed in almost 70% of the cases carrying this deletion (Calin 
et al., 2002). In a subsequent study, the same group demonstrated that the majority of 
human miRNAs are located in genomic regions associated with chromosomal 
aberrations in human cancers (Calin et al., 2004b). Further, Zhang et al. showed that a 
high proportion of genomic loci containing miRNA genes presented DNA copy 
number variations (Zhang et al., 2006).  After these early studies, several groups 
performed miRNA expression profiling and described abnormal miRNA expression as 
a frequent event in a variety of different cancer types, including solid and 
hematological tumors (Calin et al., 2006; Calin et al., 2004a; Lu et al., 2005).  
 
1.3.1 MiRNAs as oncogenes or tumor suppressor genes 
 
Similar to protein-coding genes, over-expressed or down-regulated miRNAs in cancer 
are believed to act either as oncogenes or tumor-suppressor genes, respectively (Figure 
2). However it may be inappropriate to define a single miRNA as either an oncogene or 
a tumor suppressor since the function of each miRNA might depend on the cellular 
context in which it acts.  
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1.3.1.1 Causes of miRNA deregulation 
The molecular processes involved in miRNA deregulation in human cancer are not 
clearly understood, however several of evidences indicate that multiple genetic 
mechanisms might be involved. Given their location in fragile sites of the human 
genome, miRNA alteration in cancer may be caused, for instance, by chromosomal 
aberrations such as amplification, translocation, deletion or insertion (Calin et al., 2002; 
Gauwerky et al., 1989; He et al., 2005).  
 
In addition to these mechanisms, it has been proposed that transcription factors can be 
involved in miRNA dysregulation. The tumor suppressor p53 can directly induce the 
expression of miR-34a by binding to the promoter region of the gene that generates 
miR-34a. This miRNA might be a mediator of p53’s biological effects (Raver-Shapira 
et al., 2007).  Recently a negative regulatory loop involving miR-221-222 and estrogen 
receptor α (ERα) was reported in breast cancer. High levels of miR-221-222 were 
observed in ERα-negative (ERα
-
) cells and highly aggressive breast tumors. Upon 
confirmation that ERα is a direct target of miR-221-222, ERα was found to negatively 
regulate expression of miR-221 and miR-222 by promoter binding. This feedback loop 
seems to be a regulatory mechanism involved in the development of ERα-negative 
breast cancers (Di Leva et al., 2010). Through direct binding to promoter regions, c-
myc can also modulate transcription of miRNA genes including over-expression of the 
miR-17-92 cluster or repression of a subset of miRNAs such as miR-15a, miR-29, miR-
34 and the let-7 family (Chang et al., 2008; O'Donnell et al., 2005). Interestingly, c-myc 
is in turn targeted and regulated by let-7, suggesting a regulatory double-feedback loop 
in human cancer (Sampson et al., 2007). Finally, activation of the transcriptional factor 
HIF (hypoxia-inducible factor) may cause over-expression of miR-210 in human cancer 
(Giannakakis et al., 2008). 
 
Alternatively, miRNA expression in cancer can also be affected by epigenetic changes, 
e.g. methylation of CpG islands in promoter regions. miR-127 was the first example of 
a miRNA silenced by promoter hypermethylation in bladder cancer (Saito et al., 2006). 
In the following years, the important role of the DNA methylation in regulating 
miRNA expression has been described in various tumor types. Under-expression of 
miR-34b/c in colorectal cancer is associated with CpG islands methylation (Toyota et 
al., 2008) while methylation-mediated silencing of miR-124 has been reported in 
cervical cancer (Wilting et al., 2010). Histone modifications have also been reported as 
possible regulatory mechanisms of miRNA expression in cancer cells (Nasser et al., 
2008). Interestingly, miRNAs themselves can be regulators of epigenetics changes. 
Recent studies have reported that specific miRNAs can post-transcriptionally regulate 
components of DNA methylation machinery (e.g. DNA methyltranferases –DNMTs-) 
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affecting methylation patterns observed in cancer.  The first evidence was provided in 
two studies showing that members of the miR-29 family, including miR-29a/b/c, could 
directly target DNMT3A and DNMT3B affecting global DNA methylation in lung 
cancer and acute myeloid leukemia (AML) (Fabbri et al., 2007; Garzon et al., 2009). 
Further, miR-148 was shown to target DNMT3B in HeLa cells by interacting with a 
binding site in the coding region, instead of the 3'UTR. More recently, DNMT1 was 
identified as a direct target of both miR-148 and miR-152 in human 
cholangiocarcinoma cells (Braconi et al., 2010). Nucleotide polymorphisms may also 
affect miRNA expression. Single nucleotide polymorphism (SNP) has been described 
in the pre-miR-16 causing decreased miRNA processing in CLL (Calin et al., 2005). A 
guanine/cytosine polymorphism in the pre-miR-146 was found to be associated with 
reduced mature miRNA levels and higher risk of papillary thyroid cancer (Jazdzewski 
et al., 2008).  
 
The involvement of viruses in cancer development has also been proposed. As 
previously mentioned, viruses can encode miRNAs using the miRNA machinery from 
the host cells. These miRNAs might be expressed and abundantly accumulated in 
infected cells leading to an alteration of endogeneous miRNA processing, export or 
RISC function (Andersson et al., 2005). Viruses might also trigger changes in the host 
miRNA expression profile at transcriptional level (Yeung et al., 2005) or, alternatively, 
dsRNA-binding proteins produced by viruses might interfere with the processing of 
endogenous miRNAs as it has been observed in plants (Chapman et al., 2004). 
Although, not directly responsible of deregulation of endogenous miRNAs, it is worth 
to mention that virally-encoded miRNAs can directly act as oncogenes and stimulate 
cancer development and/or progression by targeting host transcripts with tumor 
suppressive function (Kim do et al., 2007; Pfeffer and Voinnet, 2006).  
 
In addition, alteration of miRNA processing enzymes involved in miRNA biogenesis 
can influence miRNA expression and function in cancer. Over-expression of Drosha 
was observed in advanced cervical squamous cell carcinoma and was associated with 
changes in global miRNA expression (Muralidhar et al., 2007). Further, decreased 
TRBP2 levels, due to a frame-shift mutation, in colorectal cancer destabilizes the Dicer 
protein causing disruption of miRNA biogenesis (Melo et al., 2009). Recently, Martello 
et al. showed that miR-103/-107 represses expression of Dicer in breast cancer by direct 
interaction to its 3'UTR. Lower levels of Dicer protein stimulated migration and 
metastasis through inactivation of pre-miR-200 processing (Martello et al., 2010). 
Inactivating mutations in the exportin 5 gene were shown to interfere with pre-miRNA 
processing and lead to impaired mature miRNA production in cancer cells (Melo et al., 
2010). Moreover, loss of Ago2 was associated with reduced expression and activity of 
mature miRNAs in human cells (Diederichs and Haber, 2007). 
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1.3.1.2 Oncogenic miRNAs 
The first described miRNA with oncogenic properties was miR-155 (Metzler et al., 
2004), which derives from the primary transcript known as BIC (B-cell integration 
cluster). Over-expression of miR-155 was reported in a wide range of hematological 
malignancies (Garzon et al., 2008; Kluiver et al., 2005) as well as in solid tumors such 
as lung, pancreatic and breast cancer (Greither et al., 2010; Volinia et al., 2006). 
However, little is known about regulatory mechanisms that drive miR-155/BIC over-
expression. In line with the oncogenic potential of this miRNA, over-expression of 
miR-155 in transgenic mice leads to development of acute lymphoblastic leukemia, 
through down-regulation of SHIP (Src- homology 2 domain-containing inositol-6-
phosphatase) and c/EBPbeta (CCAAT enhancer-binding protein beta) (Costinean et al., 
2009). 
 
Concordant with the hypothesis that miRNAs are sitting in genomic fragile sites, the 
miR-17-92 cluster (including miR-17, miR 18a, miR 19a, miR-19b-1, miR-20a and miR-
92-1), is an example of miRNA polycistron with oncogenic functions located on human 
chromosome 13q31, a region frequently amplified in lymphomas (Ota et al., 2004). 
Members of the miR17-92 cluster have been found to be highly expressed in many 
solid tumors and hematological malignancies (Mendell, 2008). Further, the miR-17-92 
cluster was shown to promote proliferation and angiogenesis and to accelerate, in 
cooperation with c-myc, tumor development in mouse models (Dews et al., 2006; He et 
al., 2005). Different studies have reported that the miR-17-92 cluster affects cell cycle 
and proliferation regulating the E2F transcription factors family (O'Donnell et al., 
2005). Additionally, it was shown that members of this cluster can modulate the 
expression of known tumor suppressors such as PTEN (phosphatase and tensin 
homologue), p21 and the apoptotic protein Bcl2-ineracting mediator of cell death 
(BIM) (Mendell, 2008). Interestingly, down-regulation of miR-17-5p was observed in 
breast cancer cell lines. Ectopic expression of this miRNA caused decreased cell 
proliferation in breast cancer cells by translational repression of AIB1 (amplified in 
breast cancer gene 1) (Hossain et al., 2006). In addition, deletion of the miR-17-92 
chromosomal locus has been reported in breast cancer, ovarian cancer and melanoma 
(Hossain et al., 2006; Mendell, 2008). Taken together, these observations support the 
proposed hypothesis that the same miRNA might have a dual role, as oncogene or 
tumor suppressor, depending on the cellular context where it is expressed.  
 
1.3.1.3 Tumor suppressor miRNAs 
A clear example of a miRNA that acts as a tumor suppressor gene is given by the 
aforementioned miR-15 and -16. They are transcribed as a cluster and their reduced 
expression has been reported not only in CLL but also in diffuse large B-cell 
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lymphoma (DLBCL), prostate cancer and pancreatic cancer (Bonci et al., 2008a; Calin 
et al., 2002; Eis et al., 2005). The suppressor function of the miR-15a/16-1 cluster has 
been demonstrated in a number of studies showing that ectopic expression of these two 
miRNAs can dramatically reduce tumorigenicity in leukemic mouse models (Calin et 
al., 2008) and affect survival, proliferation and invasion of prostate cancer cells 
targeting BCL2 (B-cell lymphoma 2), CCND1 (cyclin D1) and WNT3A (wingless-type 
MMTV integration site family member 3A) (Bonci et al., 2008a). 
 
The let-7 family is also down-regulated in different tumor types (Iorio et al., 2005; 
Sempere et al., 2007; Takamizawa et al., 2004) and miRNA members of this family are 
located in fragile genomic sites associated with lung, breast and cervical cancer (Calin 
et al., 2004b). Moreover, functional studies support the tumor suppressor role of the let-
7 family in cancer development: high levels of let-7 family members can inhibit the 
activity of well known oncogenes such as the Ras family, HMGA2 (high mobility 
group AT-hook 2) or c-myc and induce apoptosis and cell cycle arrest (Johnson et al., 
2005; Lee and Dutta, 2007; Sampson et al., 2007). 
  
Since these early findings, other miRNAs with a tumor suppressive function have been 
discovered. To mention a few, members of the miR-29 family have been reported as 
deleted in cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia 
(AML). In CLL patients, mutations of the miR-29 precursor, affecting its processing, 
have also been reported (Calin et al., 2005). Moreover, miR-221 and miR-222 were 
found to act as tumor suppressors in erythroblastic leukemia inhibiting cell growth 
through repression of the oncogene KIT (Felli et al., 2005). However, similar to the 
dual-function previously described for miR-17-5p, these two miRNAs can promote cell 
proliferation and inhibit apoptosis in various solid tumors suppressing the function of 
different tumor suppressors such as PTEN, p27, p57 and tissue inhibitor of metallo-
proteinase 3 (TIMP3) (Fornari et al., 2008; Garofalo et al., 2009; le Sage et al., 2007). 
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Figure 2. miRNAs as oncogenes or tumor suppressors. This model shows that 
miRNAs which down-regulates tumor suppressor genes are considered as oncogenes 
and are usually over-expressed in cancer (left). On the other hand, miRNAs which 
down-regulates expression of oncogenes are considered as tumor suppressors and are 
likely to be lost or inactivated in cancer (right). Possible regulatory mechanisms 
affecting miRNA expression are indicated at the top. 
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1.3.2 Diagnostic and prognostic value of miRNAs 
 
In addition to the potential role as oncogenes or tumor suppressors in tumor 
development, a number of recent studies have proposed the use of miRNA expression 
profiles as molecular tools in tumor diagnosis and prognosis. Volinia et al. (Volinia et 
al., 2006) performed a large genome-wide miRNA profiling study on 540 samples 
including breast, lung, stomach, prostate, colon and pancreatic tumors. The results 
showed specific miRNA signatures associated with these six solid tumor types. On the 
other hand, some miRNAs were commonly deregulated between different cancers 
suggesting that they might have an essential role in carcinogenesis. Another large 
miRNA profiling study was performed by Lu and colleagues (Lu et al., 2005) using a 
bead-based hybridization technology. They evaluated the expression of 217 miRNAs in 
a group of 334 samples including multiple tumor types (mainly hematological 
malignancies) and non-neoplastic tissue as normal reference. Their findings revealed a 
general miRNA deregulation in tumor samples as compared to normal tissue and the 
presence of specific miRNA signature that could classify the tumor samples according 
to their tissue of origin. Moreover, deregulated miRNAs could clearly distinguish 
molecular subtypes or classify poorly differentiated tumors. 
  
Several studies have also shown the prognostic potential of miRNA expression in solid 
tumors and hematological malignancies. To mention a few, high expression of miR-155 
and low levels of let-7a was associated with short survival in lung cancer patients 
(Yanaihara et al., 2006). Increased expression of miR-21 was identified as an 
independent factor associated with short overall survival in colon cancer (Schetter et 
al., 2008) and a set of five up-regulated miRNAs was associated with poor outcome in 
AML patients (Garzon et al., 2008). In a recent study, Segura et al. identified a 
signature of 18 up-regulated miRNAs which was associated with longer survival in 
metastatic melanoma patients. In addition they constructed a classifier of 6 miRNAs 
that could predict post-recurrance survival in the same cohort (Segura et al., 2010). 
Further, low expression of miR-195 or increased expression of miR-483-5p in 
adrenocortical carcinoma (ACC) cases was associated with poorer disease-specific 
survival (Soon et al., 2009). 
 
Overall, miRNA profiling studies have shown the presence of miRNA signatures to 
distinguish tumors from normal tissues or to sub-classify tumors based on specific 
clinicopathological features. These differences in terms of miRNA expression appear to 
be tumor and tissue specific and enable to accurately classify and diagnose cancer 
patients and in some cases to predict their outcome. 
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In addition, miRNAs have recently been shown to be released in the peripheral 
circulation by cancer cells and can stably be present in the blood either contained 
within exosomes (Hunter et al., 2008; Taylor and Gercel-Taylor, 2008) or bound to 
Ago2 complexes (Arroyo et al., 2011). Interestingly, a number of studies identified 
miRNA signatures in serum and plasma that could distinguish patients with cancer 
from healthy controls in variety of tumor types including melanoma, DLBCL, ovarian 
and lung cancer (Kanemaru et al., 2011; Lawrie et al., 2008; Rabinowits et al., 2009; 
Taylor and Gercel-Taylor, 2008). To give an example, in a cohort of 94 melanoma 
patients, Kanemaru et al. observed that the plasma levels of miR-221 were significantly 
higher as compared to healthy controls. In addition, after surgical removal of the 
primary tumor, the levels of miR-221 in the plasma were notably decreased. Taken 
together, these data support the value of circulating miR-221 as a potential diagnostic 
biomarker in melanoma as well as a valuable marker to follow up melanoma patients 
after surgery (Kanemaru et al., 2011). Despite the promising findings in different tumor 
types, the prognostic and diagnostic potential, the functional implications and the 
optimal detection methods for circulating miRNAs are yet to be elucidated.  
 
 
1.4 MiRNAs as therapeutic targets 
 
The key role of miRNAs in tumor initiation and progression makes these small 
molecules really attractive candidates for development of therapeutic drugs. The 
potential advantages of using miRNA-based therapies in cancer treatment are today 
being widely explored. The strategies adopted to target miRNA expression in cancer 
involve the use of oligonucleotide or virus-based constructs to either inhibit the 
expression of oncogenic miRNAs or reintroduce tumor-suppressor miRNAs lost in 
cancer (Figure 3).  
 
1.4.1 Inhibition of oncogenic miRNA expression 
1.4.1.1 Antisense oligonucleotides (or antagomirs or anti-miRNAs)  
Antisense oligonucleotides act as inhibitors of miRNAs, binding to the mature miRNA 
with perfect complementarity. This interaction leads to a duplex formation, which 
sequesters the miRNAs from its mRNA targets and in some cases can induce 
degradation of the targeted miRNA. Chemical modifications of the oligonucleotides 
structure have been adopted in order to increase their stability, binding affinity and 
specificity.   
 
The first type of modification consists of the introduction of a 2'-O-methyl (2'-OMe) 
group which improves the binding affinity to RNA and partly contributes to nuclease 
resistance. In alternative, 2'-O-methoxyethyl (2'-OME)-modified oligonucleotides show 
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a higher affinity and specificity compared to their 2'-OMe analogs. The efficacy of 
these modifications was first shown by Krutzfeldt and collaborators who developed a 
2'-OMe-modifed cholesterol-conjugated antagomir against miR-122, a highly abundant 
and liver-specific miRNA. Intravenous administration of this modified antagomir in 
mice resulted in a specific, efficient and long-lasting (about 3 weeks from antagomir 
injection) silencing of miR-122. In addition, using miR-16 as target, given its 
abundance in all tissues, they demonstrated that antagomirs in vivo can reach a wide 
bioavailability and can efficiently silence miRNAs in most tissues (Krutzfeldt et al., 
2005).  
 
Another common modification is based on the incorporation of locked nucleic acid 
(LNA) monomers into the chemical structure of antagomirs. LNAs are 
conformationally 'locked' nucleotides with a methylene bridge connecting the 2'-
Oxygen and 4'-Carbon in the ribose ring. This conformation provides a significantly 
increased nuclease resistance, stabilizes the duplex structure and improves mismatch 
discrimination (Braasch et al., 2003). LNA-modified oligonucleotides have been shown 
to mediate specific inhibition of miRNA function both in vitro (Orom et al., 2006) and 
in mice (Elmen et al., 2008b). Recently, Elmen et al. (Elmen et al., 2008a) has shown 
for the first time that LNA-antagomirs can effectively silence miRNAs also in non-
human primates. This pioneering study in primates confirmed that LNA-modified 
antisense oligonucleotides are specific, stable and non-toxic when administrated 
intravenously, supporting the great potential of these compounds as therapeutics tools. 
 
1.4.1.2 miRNA sponges 
miRNA sponges (or decoy) are transcripts that contain multiple binding sites (in 
tandem) to a miRNA of interest and are transcribed from mammalian transcription 
vectors (plasmids or vectors based on lentiviruses or retroviruses). When introduced to 
the cell, miRNA sponges can saturate an endogenous miRNA and prevent the 
regulation of its natural targets. By introducing a bulge in the decoy transcripts at the 
position normally cleaved by Ago2, it is possible to increase the affinity of these 
miRNA sponges and stabilize the association with the miRISC (Ebert et al., 2007). 
Further, a single miRNA sponge can be used to silence an entire family of miRNAs 
that share the same seed sequence (Ebert et al., 2007). The silencing effect obtained by 
these sponges is comparable to those obtained by 2'-OMe- or LNA-modified 
oligonucleotides. However, unlike oligonucleotides-based miRNA silencing, miRNA 
sponges can stably inhibit miRNA expression without the need of multiple 
administrations. In addition, miRNA sponges can stably integrate into chromosomes or 
can be designed in order to become drug inducible or be under control of specific 
promoters whose expression is cell or tissue specific. 
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1.4.1.3 miR-mask antisense oligonucleotides 
The miRNA masking technology is a gene-specific strategy developed by Xiao and 
colleagues (Xiao et al., 2007). In contrast to miRNA sponges, a miR-mask is a single-
stranded 2'-O-methyl modified antisense oligonucleotide which does not directly 
interact with a specific miRNA but, instead, is fully complementary to the binding sites 
of that miRNA in the 3'UTR of the target mRNA. Thus, these modified 
oligonucleotides compete with an endogenous miRNA and mask the access to the 
binding sites of the target mRNA. Although off-target effects are reduced with this 
approach, the gene-specificity of miR-masks can be a limitation for therapeutic 
purposes since miRNAs exert their function through repression of multiple targets to 
contribute to tumorigenicity. 
 
1.4.2 Restoration of expression for tumor-suppressor miRNAs  
1.4.2.1 miRNA mimics and adenovirus-associated vectors (AVV) 
The use of synthetic oligonucleotides mimicking endogenous mature miRNA is a 
valuable approach to restore the expression of tumor suppressor miRNAs which are 
lost or down-regulated in cancer. These miRNA mimics are short, double stranded and 
2'-O-methyl chemically modified oligonucleotides. Some of them present a longer 
sequence such as miRNA precursor (e.g. pre-miRNA developed by Ambion). Several 
studies have shown how miRNA mimics can repress proliferation and promote cell 
death in cancer cell lines or effectively decrease tumorigenicity in mouse models 
(Bonci et al., 2008b; Garzon et al., 2009; Xiong et al., 2010). However there are 
presently no in vivo studies demonstrating whether miRNA mimics could be efficiently 
delivered by intravenous injection to be suitable as therapeutic tools. 
 
Adenovirus-associated vectors (AVV) represent an alternative strategy to re-establish 
the expression of tumor suppressor miRNAs in cancer cells. AVVs show a highly 
efficient gene transduction to target cells, do not integrate into the genome and can be 
efficiently eliminated with a minimal effect of toxicity as shown in clinical trials 
(Michelfelder and Trepel, 2009). Further, a recent study showed that systemic 
administration of miR-26a in a murine liver cancer model using an AVV resulted in 
apoptosis induction and cell growth inhibition without any sign of toxicity. This is the 
first report showing that restoration of tumor suppressor miRNA expression could 
repress tumor progression in vivo. Although this approach might be valuable for 
treatment of liver cancer, the efficacy of these virus-based vectors in other tumor types 
and other organs is still unknown (Kota et al., 2009). 
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Figure 3. miRNA-based approaches to modulate expression of oncogenic miRNAs (A) 
or tumor suppressor miRNAs (B). miRISC, miRNA-induced silencing complex; ORF, 
open reading frame; UTR, untranslated region; AAV, adeno-associated virus. 
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1.5 Strategies for miRNA analysis 
A number of molecular technologies are today available for discovery, identification, 
detection and characterization of miRNA species. 
  
1.5.1 Biological approaches to detect miRNAs 
1.5.1.1 Hybridization-based techniques 
1.5.1.1.1 Northern blot analysis 
Northern blot is a standard method for detection of RNA and it can be a valuable choice 
for miRNA identification after some modifications. Given the small size, in order to 
obtain a better size-based separation, polyacrylamide gels are a preferable choice rather 
than agarose gels. Further, radio-labeled (e.g. 
32
P) locked nucleic acid (LNA) probes 
are often used to increase the sensitivity (Varallyay et al., 2008). Since this technique 
involves a size-based separation, it has the advantage of detecting pri-miRNA, pre-
miRNA and the mature form in a single hybridization. However, this method is time 
consuming and is not very sensitive. It requires high amount of RNA (5-10µg) limiting 
its use for analysis of miRNAs in clinical material. Moreover, using this method, it can 
be difficult to clearly distinguish between miRNAs belonging to the same family which 
differ in only one nucleotide (e.g. let-7 family). In addition it is limited to detection of 
known miRNAs. 
 
1.5.1.1.2 In situ hybridization 
This is an alternative method used for miRNA detection in cells or tissue sections. The 
procedure is similar to conventional in situ hybridization used for mRNA detection 
with differences in the probe preparation. In both cases digoxygenin (DIG) is used to 
label the probe but for mRNA, DIG is incorporated into the probe (internal labeling) 
while for miRNA, due to the small size, DIG is added to the 3' end of the probe using 
deoxynucleotidyl transferase. In order to improve the specificity, LNAs are also 
incorporated into the probe. This method allows both detection and cellular localization 
of the miRNA of interest. However its sensitivity is relatively low and it is limited to 
detection of known miRNAs. 
 
1.5.1.1.3 Microarray analysis 
Compared to Northern blot and in situ hybridization techniques, miRNA-microarray is 
a high-throughput technology which is widely used in miRNA expression profiling 
studies. Importantly, microarrays can contain probes with different design to detect 
both precursor and mature forms of the miRNA on the same chip (Liu et al., 2004). 
Although, miRNA-microarray is a simple, efficient and relatively low-cost method to 
obtain miRNA expression profiles, only known miRNAs can be identified. 
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1.5.1.2 Quantitative Real-Time PCR (qRT-PCR) 
This method, normally used for detection of DNA or complementary DNA (cDNA), 
has been adapted for detection of mature miRNA molecules. Since they are short and 
do not contain a poly(A) tail at the 3' end, alternative strategies have been developed for 
the cDNA synthesis such as the use of stem-loop primers that hybridize to the 3' end of 
the miRNA. Alternative but less sensitive PCR methods based on poly(A) tailing for 
cDNA synthesis and SYBR-Green detection have also been developed (Chen et al., 
2011). However, qRT-PCR based on stem-loop primers is the most commonly used 
and allows a fast, easy and sensitive detection of miRNAs using a small amount of 
RNA (about 100ng). Furthermore, the stem-loop structure gives the advantage to 
discriminate between miRNAs that differ by only one nucleotide. qRT-PCR is also  
considered as the 'gold-standard' method for validation of microarray results. At 
present, stem-loop qRT-PCR assays for miRNA are also available as low-density 
arrays giving the possibility to analyze the expression of 384 miRNAs on a single plate.  
However, qRT-PCR is limited to the analysis of known miRNAs.  
 
1.5.1.3 High throughput sequencing 
Recently, different high throughput sequencing platforms (Illumina, 454 from Roche 
and SOLiD from Applied Biosystem) became available to researchers to sequence and 
profile small RNA populations. Different from the previously mentioned techniques, 
these sequencing methods are useful tools for the discovery of novel miRNAs. In 
addition, this technology allows to quantify and detect miRNA sequence variations 
(isomirs) in mature miRNAs, including RNA editing (Blow et al., 2006) and 5'/3'-end 
variations (Morin et al., 2008). All these sequencing platforms can provide enormous 
amounts of information although differences can apply for each technology in terms of 
number of small RNAs that can be profiled, the sequencing error rate and the effective 
cost. Undoubtedly, in these past few years, the deep sequencing technology has 
accelerated the biomedical research enabling a more comprehensive analysis of the 
genomes. However, at present, the elevated costs and the requirement of high bio-
informatics expertise for data management are still limitations for these high-
throughput technologies to become widespread and routinely used.  
 
1.5.2 Tools for identification of miRNA targets 
While there are many technologies available for detection and identification of miRNA, 
our knowledge on their function is still limited. In order to understand the regulatory 
role of miRNAs, computational and biological strategies for target prediction and 
validation have been developed. However the interaction between miRNA and mRNA-
target is a complex process making it more difficult to understand the mechanism of 
action of miRNAs. The major challenge to predict miRNA targets is due to the fact that 
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in animals (differently from plants) the miRNA have generally a limited 
complementarity to their targets (Ambros, 2004). The 'seed-region' at the 5' end of the 
miRNA, plays a major role in the specific interaction between miRNA and their targets 
and different kind of interactions can occur: i) Perfect base pairing of the seed region 
with an additional extensive interaction in the 3' end of the miRNA; ii) Perfect 
complementary interaction of the seed region but poor pairing in the 3' end; iii) 
Presence of a mismatch in the seed region with compensation of a more extensive 
complementary in the 3' end of the miRNA (3' compensatory) (Bartel, 2009; Maziere 
and Enright, 2007). 
 
1.5.2.1 Computational target-prediction methods  
In the attempt to identify miRNA targets a number of web-based programs have been 
developed. All these in silico methods apply different criteria for miRNA targets 
prediction such as perfect or nearly-perfect base pairing at the seed region (e.g. 
miRanda, TargetScan), evolutionary conservation of the seed sequence (e.g. 
TargetScan, PicTar), presence of multiple binding sites in the same target (e.g. 
TargetScan, miRanda), absence of secondary structure at the binding site of the target 
and favorable miRNA-target duplex thermodynamics (e.g. RNAhybrid, PicTar). Today 
it is possible to access individual softwares, and there are also online servers that 
integrate different prediction algorithms together (e.g. GOmiR, miRecords, miRGator). 
However, this integration often performs poorly as compared to the prediction by one 
single algorithm due to a significantly reduced sensitivity (Alexiou et al., 2009). 
Although, the identification of predicted miRNA target can be easy and relatively quick 
using the in silico approaches, it requires validation by biochemical techniques. The 
most commonly used programs for target prediction are summarized in Table 1. 
 
1.5.2.2 Experimental methods to identify and/or validate miRNA-target interaction 
The luciferase reporter assay is the approach most commonly used for identification of 
miRNA targets. A complete or partial 3'UTR sequence or an oligonucleotide containing 
multiple binding sites (in tandem) for the miRNA under investigation are cloned 
downstream of the luciferase gene contained in the reporter plasmid. The recombinant 
plasmid is transiently transfected in the host cells with or without over-expressing the 
miRNA of interest. When the candidate gene is an authentic target, the luciferase 
activity is decreased in the miRNA over-expressing cells as compared to the control 
cells. 
 
Another valuable technique to identify targets and uncover the biological function of 
canditate miRNAs is based on cross-linking combined with co-immunoprecipitation 
(CLIP). In principle Ago2 complexes and bound RNAs are cross-linked by ultraviolet 
light (UV) and the Ago2-RNA complexes are purified by immunoprecipitation. The 
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immunoprecipitated complexes contain both miRNA and potential mRNA target. The 
isolated RNAs can be analyzed using high throughput sequencing, microarray or qRT-
PCR. 
 
Based on the principle that miRNAs can induce mRNA degradation or translational 
repression, microarray and proteomics have been adopted to identify miRNA targets. 
These high-throughput methods allow detection of global changes in mRNA or protein 
expression respectively, in presence or absence of the miRNA of interest. However, 
microarray techniques will provide significant information for miRNA target when 
gene expression is regulated by mRNA degradation but will miss those targets which 
are regulated by translational repression. Instead these targets can be identified using a 
proteomics approach (Selbach et al., 2008). The method adopted by Selbach et al. is 
based on the stable isotope labeling by amino acids added in cell culture for short time 
(pulsed-SILAC) and relies on the incorporation of labeled amino acids into newly 
synthesized proteins. Two different isotopes, ‘heavy’ and ‘medium-heavy’, are added 
to the culture medium of the control cells and cells over-expressing the miRNA of 
interest.  During labeling, all newly synthesized proteins will be ‘heavy’ or ‘medium-
heavy’, while the pre-existing proteins present before labeling will remain in the light 
form. The miRNA targets can be identified by the ratio of heavy and medium-heavy 
isotope signal intensity. The signal intensity for the medium-heavy isotope will 
decrease whenever the mRNA is a target of the miRNA investigated, otherwise the two 
types of isotopes will produce similar signal intensity.  However, it should be noted that 
both microarray and proteomics-based methods provide indirect validation of miRNA 
target and the results still have to be verified using alternative biochemical approaches. 
(Enright et al., 2003; Friedman et al., 2009; Gaidatzis et al., 2007; Grimson et al., 2007; 
Kertesz et al., 2007; Krek et al., 2005; Lewis et al., 2005; Maragkakis et al., 2009; 
Miranda et al., 2006; Rehmsmeier et al., 2004; Wang and El Naqa, 2008) 
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2 AIMS OF THE STUDY 
 
The overall objectives of this thesis were to determine deregulation of miRNAs and 
miRNA machinery components in human cancer and to assess their role in tumor 
development and progression. Moreover, we aimed to evaluate the prognostic and 
diagnostic impact of their deregulation in human malignancies and possible 
applications in clinical practice. More specifically, we aimed to: 
 
 
Paper I. Explore the impact of microRNA deregulation in malignant melanoma by 
analyzing miRNA expression data in relation to clinical, molecular and 
histopathological characteristics. 
 
 
Paper II. Identify miRNA classifiers to distinguish adrenocortical carcinomas (ACC) 
from adenomas, evaluate the potential of deregulated miRNAs as molecular predictors 
of survival among ACC cases and elucidate the role of specific miRNAs in the 
pathogenesis of ACC.  
 
 
Paper III. Evaluate the expression levels of core components of the miRNA 
machinery, to define their value as diagnostic and/or prognostic biomarkers in 
adrenocortical tumors and explore their role in development or progression of ACC. 
 
 
Paper IV. Investigate the impact of miRNA and miRNA machinery deregulation in 
diffuse large B-cell lymphoma (DLBCL) and unravel their functional role in DLBCL 
pathogenesis.  
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3 MATERIALS AND METHODS 
 
3.1 Patients, clinical material and cell lines 
 
In this thesis, clinical tissue samples and established cell lines were used to study 
human tumors including metastatic melanoma, adrenocortical tumors and diffuse large 
B-cell lymphoma (DLBCL). 
 
Tissue material for metastatic melanoma was collected at the Karolinska University 
Hospital in Sweden while melanoma cell lines were kindly provided by Dr. Monica 
Rodolfo (INT, Milan, Italy) (Paper I). Adrenocortical tumor samples and normal 
adrenocortical cortices were obtained from the Karolinska University Hospital in 
Sweden (Papers II and III). DLBCL cases were received from Uppsala University 
Hospital in Sweden and the anonymous reactive lymph nodes were obtained from 
Karolinska University Hospital and Uppsala University Hospital (Paper IV). 
 
Twenty-one non-commercially available melanoma cell lines were included in Paper I. 
The cells were derived from primary melanomas, lymph node metastases or cutaneous 
metastases and were propagated in culture for 18 passages in average. The NCI-H295R 
adrenocortical cancer cell line, used in Paper II and III, was purchased from the 
American Type Culture Collection (ATCC; LGC Standards, Middlesex, UK). The four 
established de novo DLBCL cell lines (OCI-Ly-1, OCI-Ly-3, OCI-Ly-7 and OCI-Ly-
10) in Paper IV were kindly provided by Dr Mark Minden (University Health 
Network, Toronto, Canada). OCI-Ly-1 and OCI-Ly-7 are GCB-subtype while OCI-Ly-
3 and OCI-Ly-10 are ABC-subtype. 
 
3.1.1 Cutaneous metastatic melanoma (Paper I) 
 
Cutaneous metastatic melanoma is a highly aggressive tumor, which originates from 
melanocytes and is responsible for the majority of skin tumor-related deaths worldwide. 
Despite the improvement in our understanding of biological processes of malignant 
melanoma tumorigenesis, the prognosis of patients with advanced disease is still poor 
(Garbe and Eigentler, 2007) and early diagnosis, based on Breslow’s tumor thickness 
and sentinel lymph node status, together with early surgical removal is still the best 
treatment to reduce mortality. Activating BRAF mutations (V600E), which affect the 
mitogen-activated protein kinase (MAPK) pathway, are present in 60-70% of 
malignant melanomas (Davies et al., 2002). NRAS mutations are also detected in 15-
30% of melanoma tumors (Chin et al., 1999) and cause constitutive activation of the 
MAPK pathway independently of BRAF. Inhibitions of mutated BRAF or NRAS are 
promising and novel therapeutic tools for the treatment of malignant melanoma. 
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In this study, a total of 32 fresh frozen regional lymph node metastases and 21 
melanoma cell lines were analyzed in terms of miRNA expression. Human melanocyte 
cultures (PromoCell, Heidelberg, Germany) from three different individuals were 
included as non-neoplastic reference. 
 
3.1.2 Adrenocortical carcinoma (Papers II and III) 
 
Adrenocortical tumors derive from the cortex of the adrenal gland and are often 
incidentally detected as biochemical and clinically asymptomatic adrenal masses. The 
majority of these tumors are adenomas, which can be hormonally inactive or over-
produce e.g. aldosterone (aldosteronoma) or cortisol (Cushing), while only a small 
proportion is classified as carcinomas (ACC).  While the annual incidence is low with 
4-12 cases per million among adults (Grumbach et al., 2003), ACC is an aggressive 
tumor associated with poor prognosis (Bertherat et al., 2006). Further, in the absence of 
invasion and/or distant metastases, the distinction between ACC and adrenocortical 
adenomas can be challenging and relies on histopathological evaluation and Weiss 
score classification (Weiss et al., 1989). Moreover, prognostic and diagnostic 
biomarkers for early detection of ACC are still lacking in clinical practice.  
 
A variety of studies have recently shown the potential of mRNA and miRNA profiling 
to correctly classify adenomas and carcinomas and to identify subgroups of ACC 
patients with different survival and outcome. To date over-expression of the insulin-like 
growth factor 2 gene (IGF2) was observed in more than 80% of the ACC cases. 
Expression levels of DLG1 (discs large homolog 1) and PINK1 (PTEN induced 
putative kinase 1) genes were associated with clinical outcome in ACC. Further, 
increased expression of miR-483-3p/-5p and under-expression of miR-195 was reported 
in ACC cases. (de Fraipont et al., 2005; de Reynies et al., 2009; Giordano et al., 2009; 
Laurell et al., 2009; Ozata et al., 2011; Patterson et al., 2011; Soon et al., 2009; Tombol 
et al., 2009). 
 
In our studies, 73 frozen primary sporadic tumors from 72 patients were included. In 
addition, 10 histopathologically verified normal adrenal cortical samples were used as 
non-neoplastic references. These samples were obtained from 10 patients undergoing 
nephrectomy for other reasons at the Karolinska University Hospital.  
 
3.1.3 Diffuse large B-cell lymphoma (Paper IV) 
 
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive lymphoma. It is the 
most common type of lymphoma accounting for approximately 40% of B-cell 
lymphoma cases among adults in the Western countries (Coiffier, 2001). The majority 
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of DLBCLs occur as de novo while a small proportion can progress from a previous 
indolent lymphoma such as follicular lymphoma. DLBCL is a heterogeneous group of 
lymphomas and is characterized by numerous chromosomal aberrations and genomic 
alterations. Among others, the translocation t(14;18)(q32;q21) which induces BCL2 
over-expression is frequently found (Rantanen et al., 2001). Rearrangements involving 
the locus for BCL6 in 3q27 or somatic mutations in its regulatory sequences have also 
been reported (Pasqualucci et al., 2001). Further, mutations in the TP53 gene have been 
described in DLBCL and associated with poor prognosis (Leroy et al., 2002). In 
addition, based on mRNA or miRNA expression profiling, DLBCL can be genetically 
classified in three major subtypes: germinal center B cell-like (GCB), activated B cell-
like (ABC) and type 3 of which the GCB subgroup shows a better prognosis (Alizadeh 
et al., 2000; Lawrie et al., 2007; Malumbres et al., 2009; Rosenwald et al., 2002). 
 
In this study, 75 frozen tumor biopsies from primary DLBCL cases were analyzed. 
Paraffin embedded material for 22 specimens from the same series were also collected 
for immunohistochemical analysis. Among the tumor cases, 56 were de novo DLBCL 
while 19 were classified as transformed from follicular lymphoma. Ten anonymized 
samples of reactive lymph nodes were included in the study as references of non-
neoplastic lymphatic tissue. 
  
 
3.2 Methods 
 
3.2.1 Microarray (Papers I, II and IV) 
 
miRNA microarray is a high-throughput method for studying miRNA expression 
profiles in cultured cells or tissues. This is an efficient method, which offers the 
possibility to measure the expression of all known miRNAs simultaneously in a large 
cohort of samples at a relatively low cost. 
 
In Papers I, II and IV, global miRNA expression profiling was performed using the 
Agilent human miRNA microarray platform (Agilent, Santa Clara, CA). This platform 
is a sensitive microarray-based assay, which requires very low amount of RNA input 
(100ng of total RNA) without the need of additional amplification or size fractionation 
steps. The labeling method is based on an enzymatic reaction (T4 RNA ligase) that 
attaches a single fluorophore-labeled nucleotide (pCp-Cy3) to the 3' end of each 
miRNA. This novel probe design allows a highly efficient detection of mature 
miRNAs. The probes are characterized by the addition of a guanosine (G) to their 5' 
end, which is complementary to the cytosine (C) added to the 3' end of each miRNA 
during the labeling. This G-C interaction allows to reach a melting temperature of about 
55°C for almost all mature miRNAs. Different length of the probes is an additional 
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mean to normalize the melting temperature for all different miRNAs. Furthermore, a 
hairpin structure is present at the 5' end of the probes. This particular conformation 
destabilizes the hybridization to larger non-target RNAs and stabilizes the probe-target 
interaction. Features of the probe design are shown in Figure 4. 
 
The experimental procedure included in brief: 120ng of total RNA were labeled with 
cyanine 3-pCp, hybridized onto arrays for 18-20h at 55°C, followed by washings 
according to the manufacturer’s instructions. Slides were subsequently scanned using 
an Agilent microarray scanner G2565B and the images were processed with Feature 
Extraction Software v10.7.3.1 (Agilent). The miRNA intensity values were normalized 
and median centered using Cluster 3.0 software (de Hoon et al., 2004). Hierarchical 
clustering and generation of heat maps was performed with Cluster 3.0 and visualized 
through Treeview v1.60 (http://rana.lbl.gov/EisenSoftware.htm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
Figure 4. Schematic illustration of the probe design for the Agilent miRNA microarray 
platform [Modified from (Wang et al., 2007)]. 
 
 
3.2.2 Quantitative real-time PCR (qRT-PCR) (Papers I-IV) 
 
Quantitative real-time PCR is a method to determine the amount of DNA or cDNA in a 
given sample through a PCR reaction. There are two types of qRT-PCR:  one is a 
probe-based real-time PCR, which requires a set of specific primers and an additional 
fluorogenic probe (e.g. TaqMan PCR; Applied Biosystems, Foster City, CA). The other 
category includes intercalator-based PCR, also called SYBR Green, which involves the 
use of a dye, which binds to the newly synthesized double-stranded DNA during the 
PCR reaction and gives fluorescence. Although more expensive, the TaqMan method is 
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more accurate compared to SYBR Green. The TaqMan and SYBR Green methods are 
illustrated in Figure 5. 
 
In Papers I, II and IV microarray results were validated by quantifying the expression 
levels of selected mature miRNAs by qRT-PCR. In addition, in Papers III and IV, 
quantitative real-time PCR was adopted to evaluate mRNA expression of specific genes 
of interest (e.g. DROSHA, DICER, TRBP2, DGCR8, PACT, IGF2 and H19). 
Quantification of miRNAs using TaqMan assays follows a two-step RT-PCR 
procedure: Step 1) cDNA is synthesized from 25ng of total RNA using a stem-loop RT 
primer specific to the miRNA of interest and reagents contained in the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystem). The structure of the primer 
makes the assay more specific and provides a longer template for the following step. 
Step 2) During the PCR step, cDNA is amplified using predesigned TaqMan 
MicroRNA Assays (Applied Biosystems). The peculiarity of TaqMan assays consists 
in the presence of a TaqMan minor groove binder (MGB) probe which, during PCR, 
anneals specifically to the target between the forward and the reverse primer. The probe 
contains a reporter dye (FAM-dye) at the 5' end and a MGB linked to a non-fluorescent 
quencher (NFQ) at the 3' end. During the amplification step, the DNA polymerase 
cleaves the probes that are hybridized to the template causing the separation of the 
reporter from the quencher, which results in increased fluorescence. In our studies, each 
miRNA analyzed was normalized to the expression levels of RNU6B (RNA, U6 small 
nuclear 2). Analysis of mRNA expression follows the same principle; however higher 
amount of starting material is required (100ng of total RNA) and random hexamers are 
used for the cDNA synthesis (included in the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). qRT-PCR adopts specific primers for each 
gene of interest. In our studies, normalization was done against 18S. 
 
In order to quantify the relative expression of primary and precursor forms of two 
miRNAs (miR-155 and miR-146a), we adopted SYBR Green approach as previously 
described (Schmittgen et al., 2004). The expression levels of pre-miRNAs were 
calculated based on the following formula: 
 
Pre-miRNA = 2
-CT (pri-miRNA + pre-miRNA)
 - 2
-CT (pri-miRNA) 
 
Further, the processing efficiency was calculated as the ratio of mature to precursor for 
both miR-155 and miR-146a. In all studies the relative expression levels for both 
miRNAs and mRNAs were determined using CT method and reported as 2
-ΔCT
.   
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Figure 5. Chemistry of TaqMan and SYBR Green qRT-PCR methods. (A) Illustration 
of TaqMan two steps qRT-PCR method to quantify miRNAs (left) or mRNAs (right). 
P, DNA polymerase; NFQ, non-fluorescent quencher; MGB, minor groove binder; R, 
reporter. (B) Illustration of SYBR Green qRT-PCR. P, DNA polymerase; S, SYBR 
Green dye. 
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3.2.3 Western blot analysis (Papers II-IV) 
 
The Western blot (also called protein immunoblot) is a commonly used technique to 
detect specific proteins in tissues or cells extracts. In Papers II and III, Western blot 
was performed to evaluate expression levels of BBC3/PUMA (BCL2 binding 
component 3), TRBP2, DICER or DROSHA in a series of adrenocortical tumors or 
NCI-H295R cell line. In Paper IV, Western blot was used to measure levels of miRNA 
machinery protein in four de novo DLBCL cell lines. 
 
Briefly, about 60µg of cell lysate from cells or tissue samples were separated in Tricine 
gels (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes (LC2001; 
Invitrogen). The membrane was subsequently incubated with a primary antibody 
against the protein of interest followed by incubation with a secondary antibody, which 
recognizes a species-specific proportion of the primary antibody. The secondary 
antibody is linked to a horseradish peroxidase, which, in presence of an appropriate 
substrate, generates luminescence in proportion to the amount of protein. GAPDH 
(glyceraldehydes-3-phosphate dehydrogenase) protein was used for normalization and 
protein levels were quantified on X-ray films from immunoblots using ImageJ software 
(http://rsb.info.nih.gov/ij/).   
 
3.2.4 Immunohistochemistry (IHC) (Paper IV) 
 
Immunohistochemistry is a technique for detection and localization of proteins in cells 
of a tissue section using specific antibodies. In Paper IV, IHC was performed as 
previously described (Berglund et al., 2002; Berglund et al., 2005), to evaluate the 
expression levels of CD10, Bcl-6, IRF-4 and Bcl-2 in 22 de novo DLBCLs in order to 
sub-classify the cases into GC or non-GC phenotype (Hans CP et al., 2003). The 
expression was considered as positive if >30% of tumor cells showed immunoreactivity 
for CD10, Bcl-6 or IRF-4 and >50% for Bcl-2.  
 
3.2.5 Transfection experiments in established cell lines (Papers II-IV) 
 
In Papers II and III, pre-miR Precursor or anti-miR Inhibitors (Applied 
Biosystems/Ambion) were used for in vitro studies to evaluate phenotypic effects or 
mRNA target identification in NCI-H295R adrenocortical carcinoma cells. 
 
Pre-miR precursors are chemically modified double-stranded RNA molecules which 
mimic endogeneous mature miRNAs up-regulating their activity. Once introduced in 
the cells, the special design of these molecules allows the strand with the same 
sequence of the mature miRNA of interest to be incorporated in the RISC complex, 
which is responsible for the miRNA activity. On the other hand, anti-miR inhibitors are 
chemically modified single stranded nucleic acids that can specifically bind and inhibit 
 34 
expression of endogeneous miRNAs. Specifically, miR inhibitors anti-483-3p or anti-
483-5p or miR precursors pre-miR-195 or pre-miR-497 were electroporated in NCI-
H295R cells using Nucleofector Technology (Amaxa Biosystems, Gaithersburg, MD). 
Transfection efficiency was evaluated by measuring the expression levels of miR-483-
3p, miR-483-5p, miR-195 or miR-497 using qRT-PCR. Consequences of miRNA 
expression alteration were evaluated on cell proliferation and apoptosis (Paper II). 
 
Further, in Paper III, we determined the effects of miR-195 or miR-497 over-
expression on the expression levels of potential targets such as TRBP2 and DICER. 
In Papers III and IV, NCI-H295R cells were also transfected by electroporation using 
siRNA molecules (Santa Cruz Biotechnology Inc.).  The siRNAs consist of a pool of 
three 19-25nt long RNA molecules designed to knock down the expression of TRBP2. 
Our purpose was to inhibit the expression of TRBP2 in NCI-H295R cells (Paper III) 
or in DLBCL cell lines, OCI-Ly-1 and OCI-Ly-3, (Paper IV) and to subsequently 
evaluate whether cell growth and/or apoptosis could be affected.  
 
3.2.6 Quantification of cell proliferation and apoptosis (Papers II-IV) 
 
Malignant cancer cells grow in uncontrolled manner, become resistant to 
programmed cell death (apoptosis) and acquire the ability to invade adjacent tissues 
and to metastasize. To evaluate the importance of TRBP2 in tumor development, we 
investigated the effects of TRBP2 inhibition on cell proliferation and apoptosis in 
NCI-H295R adrenocortical cancer cell line or in de novo DLBCL cells (Papers III 
and IV). Further, in Paper II we also evaluated the consequences of miR-483-3p and 
miR-483-5p inhibition or miR-195 and miR-497 over-expression on cell growth and 
apoptosis.  
 
Cell proliferation was measured using WST-1 (4-(3-(4-iodophenyl)-2-(4 nitrophenyl)-
2H-5-tetrazolio)-1,3-benzene disulfonate (Roche Applied Science, Mannheim, 
Germany) colorimetric assay. This is a nonradioactive assay based on the cleavage of 
tetrazolium salt WST-1 by viable cells. Therefore, the amount of formazan dye formed 
directly correlates to the number of metabolically active cells in the culture. Compared 
to other methods such as MTT (3-4,5-Dimethylthiazol-2-yl)-2-5-diphenyltetrazolium) 
assay, WST-1 colorimetric assay has many advantages: a) It does not require 
solubilization steps before the detection; 2) it is more sensitive than MTT; and 3) it is 
less toxic to the cells. 
 
To perform the proliferation assay, cells were seeded in 96 wells plates and 20 µl of 
tetrazolium WST-1 was added into 200 µl of cultured cells 48h (for de novo DLBCL 
cells) or 72h (for NCI-H295R cells) after transfection. After incubation at 37°C, 
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absorbance was determined using a microplate ELISA reader. The measured 
absorbance directly correlates to the number of viable cells. 
 
For detection of apoptosis, caspase-3 colorimetric assay (Genscript, Poscataway, NJ, 
USA) was performed. This is a simple method to detect the activity of Caspase-3, 
which belongs to a family of proteases with an important role in apoptosis. The assay 
is based on spectrophotometric detection of the chromophore p-nitroaniline (pNA) 
which is released from the substrate DEVD after cleavage by Caspase-3 (or 
DEVDase). The yellow color produced by free pNA is proportional to the amount of 
Caspase-3 activity in the sample analyzed. For detection of apoptosis, lysates 
containing 50µg protein were mixed with reaction buffer and Caspase-3 substrate for 
4h at 37°C. Absorbance was determined using a microplate ELISA reader. 
 
3.2.7 Argonaute 2 (Ago2) immunoprecipitation and analysis of Ago2-associated 
mRNAs (Paper III)  
 
Protein-RNA interactions play an important structural and regulatory role in the cells 
and immunoprecipitation (IP) is a valuable method to study these types of interactions. 
In Paper III, we performed immunoprecipitation of Ago2 in NCI-H295R cells upon 
over-expression of miR-195 or miR-497 to determine whether TRBP2 and DICER were 
direct targets for these two miRNAs. This protocol is based on the notion that Ago2 
complexes can stably associate with miRNA targets (Beitzinger et al., 2007; Karginov 
et al., 2007). Thus, cells over-expressing miR-195 or miR-497 should show an 
enrichment of TRBP2 and DICER mRNAs in the Ago2 immunoprecipitates in 
comparison to cells transfected with control molecules. In principle this method 
consists in combining UV RNA-protein crosslinking with immunoprecipitation using a 
specific antibody against Ago2 followed by the isolation of the crosslinked RNA. 
Detection of RNA transcripts can be performed using different techniques such as 
sequencing, microarray or qRT-PCR. 
 
In our study, TRBP2 and DICER mRNA levels were measured by qRT-PCR and 
normalized to 18S. The enrichment of the two mRNAs binding to Ago2 was calculated 
by dividing the relative amount of mRNA in the IP samples and the amount of mRNA 
in the corresponding input samples. 
 
3.2.8 Genomic DNA sequencing for mutation screening (Paper III) 
 
Genomic DNA sequencing, using the chain-terminator method (also named Sanger 
method after its developer Frederick Sanger in the early 1970s), was performed in 
Paper III to identify possible mutations in the TRBP2 gene.  
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This method is based on the use of dideoxynucleotides (ddNTPs) in addition to the 
normal nucleotides (NTPs) present in DNA molecules. ddNTPs basically share the 
same structure as nucleotides with the exception that they contain a hydrogen group on 
the 3’ carbon instead of a hydroxyl group. This modification prevents the addition of 
further nucleotides terminating the DNA chain elongation. During the sequencing 
reaction, the ddNTPs (ddATP, ddCTP, ddGTP and ddTTP) are randomly incorporated 
in the growing DNA sequence leading to generation of DNA fragments of different 
length. All DNA fragments are subsequently separated according to size using 
automated capillary sequencers. The four ddNTPs can be easily detected due to their 
different absorbance and the sequencing results are displayed as chromatograms.  
In this study, we sequenced all coding exons and flanking exon-intron junctions of the 
TRBP2 gene in a cohort of 23 ACCs.  
 
3.2.9 TaqMan copy number assay (Paper III) 
 
Copy number variation is associated with genetic diseases such as cancer. In paper III, 
TaqMan copy number assay (Applied Biosystems) was performed to evaluate changes 
of TRBP2 copy number in normal adrenal cortices and adrenocortical tumors. In brief, 
genomic DNA is amplified simultaneously using a TaqMan copy number assay 
specific to the gene of interest and a TaqMan copy number reference assay (RNase P), 
which detects a sequence known to be present in only two copies in the genome. The 
number of copies of the target sequence in each sample is calculated using the 
comparative CT method. 
 
3.2.10 Statistical analyses (Papers I-IV) 
 
In all four studies, statistical analysis was performed using Statistica 8.0 (StatSoft, Inc., 
Tulsa, OK) or MS Office Excel. For miRNA microarray data analysis two statistical 
methods were applied: Significance Analysis of Microarrays (SAM) (http://www-
stat.stanford.edu/Btibs/SAM/) and Prediction Analysis of Microarrays (PAM) 
(http://www-stat.stanford.edu/Btibs/PAM/). SAM identifies set of genes, which show 
statistically significant differences in expression between sample groups. Each gene is 
given a score called false discovery rate (FDR). In our studies, SAM was performed 
to identify specific miRNAs associated with sample groups, 
molecular/histopathological and clinical features. PAM is a statistical method for class 
prediction based on expression data. In our case, PAM was used to determine miRNA 
classifiers that best could classify sample groups. Unpaired student’s t-test was used to 
compare differences in mRNA or miRNA expressions, evaluated by qRT-PCR, 
between sample groups while paired student’s t-test was performed to analyze 
transfection experiments. Pearson’s correlation was used to assess correlation between 
microarray and qRT-PCR results or to evaluate correlation between mRNA and protein 
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levels. The association between mRNA or miRNA expression and clinical-
histopathological parameters was analyzed using 
2
-test. Association between mRNA 
or miRNA expression and patient outcome was studied using Kaplan-Meier plots, and 
survival curves for each group were compared using the log-rank test. Overall survival 
was defined as the period (months) from the time of diagnosis until the end of follow-
up or death of the patient. Survival was censored if patients were still alive or died for 
unrelated reasons. Disease-free survival was the time between the initial diagnosis and 
the end of follow-up or documented recurrence. Survival was censored if patients did 
not show any recurrence or died for other causes not related to disease. In all studies, p-
values < 0.05 were considered as significant and were 2-tailed. 
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4 RESULTS AND DISCUSSION 
 
4.1 Paper I. MicroRNA expression profiles associated with mutational status 
and survival in malignant melanoma 
 
Evidence of miRNA expression alteration in cutaneous melanoma was previously 
reported in a few studies (Gaur et al., 2007; Mueller et al., 2009). However, at the time 
when we carried out this study, data on miRNAs in melanoma were limited to cell 
lines. Here, we performed a genome-wide miRNA expression profiling in both clinical 
material (16 melanoma lymph node metastases) and 21 melanoma cell lines in 
comparison to cultured melanocytes in order to improve our knowledge of miRNA 
deregulation in melanoma development and impact on patient survival. Microarray 
results were subsequently validated in an independent cohort of 16 additional 
melanoma samples.  
 
We demonstrated that both clinical melanoma samples and cell lines have clearly 
distinct miRNA expression patterns in comparison to non-neoplastic melanocytes. 
However, considerable differences in miRNA profiles were observed between clinical 
samples and cell lines possibly due to effects of culturing conditions or cell type 
heterogeneity within the clinical material. Nevertheless, cell lines and melanoma 
samples showed commonly deregulated miRNAs. Among others, we observed a 
significant under-expression of miR-211 in both clinical samples and melanoma cell 
lines compared with melanocytes. Interestingly, miR-211 seems to be one of the most 
consistently under-expressed miRNAs in melanoma and recently different studies 
highlighted its important regulatory role in melanoma invasiveness and metastasis. 
 
Since activating mutations in components of mitogen-activated protein kinase pathway 
are commonly found in melanoma (Chin et al., 1999; Davies et al., 2002), we 
additionally aimed to find possible correlations between deregulated miRNA in 
melanoma and mutations in BRAF or NRAS. We found that low expression of miR-
193a, miR-338 and miR-565 was associated with cases carrying BRAF
V600E
 mutation 
while reduced expression of miR-663 was associated with NRAS-mutated cases (Figure 
6). However, we did not identify any miRNA commonly deregulated in BRAF and 
NRAS mutated melanomas suggesting that BRAF and NRAS might contribute to 
melanoma development through regulation of distinct signaling pathways.  
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Figure 6. Heat maps showing miRNAs associated to BRAF and NRAS mutational 
status. [Modified from (Caramuta et al., 2010)]. 
 
 
In our cohort of samples, miR-193a could best discriminate BRAF-mutated from wild-
type melanomas; interestingly, an association between BRAF
V600E
 mutation and under-
expression of miR-193a has been also reported in thyroid cancer cells (Cahill et al., 
2007). These observations suggest that this miRNA may have a common role in 
BRAF-associated signaling pathways in different tumor types. 
 
Survival information was available for all the patients included in the study. We then 
searched for a miRNA signature that could separate melanoma patients with short 
survival. A univariate analysis was initially performed on a cohort of 16 patients (8 
short survival, range 1-12 months and 8 with good prognosis and long survival, range 
60-134 months) using microarray data, and subsequently verified by qRT-PCR. Our 
results showed that low expression of miR-191 combined with high levels of miR-193b 
were associated with poor survival in melanoma patients. The prognostic value of this 
miRNA signature was additionally confirmed in an independent cohort of 16 
melanoma patients. Association of low miR-191 and high miR-193b expressions with 
melanoma-specific survival is shown in Figure 7.  
 
In conclusion our study shows a frequent deregulation of miRNA expression in lymph 
node metastases of malignant melanoma with associations to BRAF and NRAS 
mutational status. Moreover, we identified a two-miRNA signature that could predict 
specific survival in metastatic melanoma patients. 
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Figure 7. Association between miRNA expression levels and survival in melanoma. 
Kaplan-Meier plots illustrate the significant associations between low miR-191 (left) 
and high miR-193b (right) expression and poor melanoma-specific survival in a 
cohort of 32 melanoma cases. [Modified from (Caramuta et al., 2010)].  
 
 
4.2 Paper II. The role of microRNA deregulation in the pathogenesis of 
adrenocortical carcinoma 
 
In this study, we characterized miRNA expression profiles in adrenocortical carcinoma 
(ACC) in comparison to adenomas and normal adrenal cortex and determined the 
implication for patient’s survival.  
 
Microarray analysis, in a cohort of 48 adrenocortical tumors (16 adenomas and 22 
carcinomas) and 4 normal adrenal cortices, showed distinct miRNA expression profiles 
between ACC and non-carcinoma samples. Among the most significantly deregulated 
miRNAs, we identified miR-483-3p, miR483-5p, miR-497 and miR-195. miR-483-3p 
and miR-483-5p derive from different arms of the same miRNA precursor while miR-
195 and miR-497 are generated from the same miRNA cluster and are co-expressed 
suggesting that they may share common transcriptional regulators and similar 
biological functions. Over-expression of miR-483-3p/-5p and down-regulation of miR-
497-195 cluster in ACC as compared to adenomas or normal cortices was additionally 
verified in an extended cohort of samples by qRT-PCR. In support of our findings, 
deregulation of these miRNAs was reported in adrenocortical tumors as well as a 
variety of other tumors, suggesting that altered expression miR-483-3p/-5p and miR-
497-195 cluster may be a common feature in several tumor types (Doghman et al., 
2010; Flavin et al., 2009; Lehmann et al., 2010; Patterson et al., 2011; Soon et al., 
2009). 
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Beside the association with expression levels, we also investigated the biological role of 
these deregulated miRNA in the pathogenesis of ACC. We showed that ectopic 
expression of miR-195 or miR-497 and inhibition of miR-483-3p or miR-483-5p could 
significantly reduce cell growth in NCI-H295R human ACC cells. In addition, we 
observed that over-expression of miR-195 or miR-497 and reduced expression of miR-
483-3p, but not miR-483-5p, promoted programmed cell death. Interestingly, effect on 
cell proliferation and apoptosis, upon repression of miR-483-3p expression, was 
previously shown in hepatocarcinoma cells (Veronese et al., 2010). In the same study, 
Veronese and colleagues identified BBC3/PUMA, a tumor suppressor involved in 
apoptosis regulation, as a miR-483-3p target. Notably, we showed a significant inverse 
correlation between miR-483-3p and PUMA expressions in adrenocortical tumors 
suggesting a possible miRNA-mRNA target relationship also in this tumor entity 
(Figure 8). 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Role of miR-483 in ACC. (A) Effect on cell proliferation and apoptosis upon 
inhibition of miR-483 expression. (B) Correlation between expression of miR-483-3p 
and its putative target PUMA. [Modified from (Özata et al., 2011)]. 
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In this study, we also demonstrated that miRNA expression profiles could sub-classify 
ACCs according to their clinical outcome. Specifically, using a classifier of 11 
miRNAs identified by SAM survival analysis, the 25 ACC cases analyzed were 
clustered in three distinct groups, of which one of them included most of the ACC cases 
who died of disease and was associated with poorer survival. The prognostic value of 
these miRNAs was verified evaluating their expression by qRT-PCR. Kaplan Meier 
survival curves combined with log-rank test analysis confirmed a significant 
association of high expression of three miRNAs (miR-503, miR-1202 and miR-1275) 
with poorer survival (Figure 9).  
 
In conclusion, we found additional miRNAs associated with ACC and partly elucidated 
the functional role of miR-483, miR-195 and miR-497 in the pathogenesis of ACC. In 
addition, we identified novel miRNAs associated with poor survival in ACC which 
may have an important role in patient’s management and choice of therapeutic strategy. 
 
A 
 
 
 
 
B 
 
Figure 9. miRNAs associated with survival in carcinoma patients. (A) Identification of 
3 clusters based on miRNA expression and subsequent Kaplan-Meier analysis for cases 
in Cluster 1, Cluster 2 and Cluster 3. (B) Kaplan-Meier curves for miR-503, miR-1202 
and miR-1275 based on qRT-PCR results. [Modified from (Özata et al., 2011)]. 
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4.3 Paper III. Clinical and functional impact of TRBP2 over-expression in 
adrenocortical carcinoma 
 
We, and others, have previously shown the diagnostic and prognostic impact and 
functional role of deregulated miRNAs in adrenocortical tumors. In addition, recent 
studies have also demonstrated frequent alteration of miRNA processing factors, 
required for miRNA maturation, in cancer and shown their important role in 
development and progression of different tumor types. 
 
Here, we investigated the expression of miRNA machinery’s core components in a 
cohort of 73 adrenocortical tumors (43 adenomas and 30 ACCs) and 9 normal adrenal 
gland cortices using qRT-PCR and Western blot approaches. We observed a significant 
over-expression of TRBP2, DICER and DROSHA, both at mRNA and protein levels, 
in ACC cases as compared to adenomas and normal tissues (Figure 10). However, 
while increased expression of TRBP2, DICER and DROSHA was found in some tumor 
types, a few studies showed low expression of these miRNA machinery components in 
other human malignancies such as ovarian, lung and gastric cancers (Chiosea et al., 
2006; Fu et al., 2010; Karube et al., 2005; Melo et al., 2009; Merritt et al., 2008; 
Muralidhar et al., 2007). These observations may suggest a tissue-specificity 
deregulation of TRBP2, DICER and DROSHA, implying a potential dual role as tumor 
suppressors or oncogenes in different human cancers. 
 
 
 
 
Figure 10. Box plots showing relative mRNA expression levels for TRBP2, DICER, 
and DROSHA in adrenocortical tumors and adrenal cortices. 
 
 
A major challenge in diagnosis of adrencortical tumors is to distinguish between 
localized carcinomas and tumors that are simply adenomas. Here, in order to evaluate 
the prognostic value of TRBP2, DICER and DROSHA in adrenocortical tumors we 
performed Kaplan-Meier analysis of disease-free survival on a cohort of 45 non-
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metastatic adrenocortical tumors. Our results demonstrated that, among the three genes 
analyzed, TRBP2 was the best predictor of ACC (Figure 11). 
Thus, expression of TRBP2 may be of clinical relevance in addition to other clinical 
tools currently in use for management of adrenocortical carcinomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Prediction of carcinomas based on the mRNA expression levels of TRBP2. 
The Kaplan-Meier curves separate the patients according to the expression levels of the 
molecular predictors TRBP2. 
 
 
Moreover, in agreement with the increased expression in ACC patients, we showed that 
repression of TRBP2 levels affected cell growth and promoted apoptosis in NCI-
H295R cell line. These data further suggest the oncogenic activity of TRBP2 and its 
possible role in the pathogenesis of ACC. 
 
Beside its biological function, we also unraveled possible molecular mechanisms that 
regulates TRBP2 expression in ACC. Copy number gain, analyzed using Taqman copy 
number assay, was observed in 57% of the ACC cases suggesting that copy number 
abnormality may be partly responsible for the TRBP2 over-expression. In addition, we 
demonstrated that ectopic expression of miR-195 or miR-497 can modulate TRBP2 
expression in NCI-H295R cells. In our previous study (Paper II) we have shown that 
miR-195 and miR-497 can regulate cell growth and apoptosis in ACC cells. Taken 
together, our findings may suggest phenotypic effect observed in adrenocortical cancer 
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cell line upon alteration of miR-195 and miR-497 expression might be mediated 
through TRBP2 down-regulation. However, gene mutations were not observed 
suggesting that this is not an additional mechanism of TRBP2 expression regulation. 
 
In conclusion, we showed over-expression of TRBP2 as a frequent event in ACC and 
demonstrated its functional role in pathogenesis of this tumor type. Further, we found 
that TRBP2 mRNA expression is a valuable predictor of malignancy in adrenocortical 
tumors demonstrating its relevance as a potential novel biomarker in the prognosis of 
ACC. 
 
4.4 Paper IV. Role of microRNAs and microRNA machinery in the 
pathogenesis of diffuse large B-cell lymphomas 
 
Diffuse large B-cell lymphoma (DLCBL) is a type of B-cell lymphoma characterized 
by a highly heterogeneous genetic background. miRNA alterations in DLCBL, has 
been previously reported (Lawrie et al., 2009; Lawrie et al., 2007; Roehle et al., 2008). 
However, the role and the clinical impact of miRNAs and their processing factors in 
this type of lymphoma are still not fully understood.  
 
In this study we analyzed, using microarray and qRT-PCR approaches, miRNAs and 
their processing factors expressions in a cohort of 75 DLBCLs (56 de novo and 19 
transformed) and 10 reactive lymph nodes used as references of non-neoplastic 
lymphatic tissue (LN). Our results show clearly different miRNA patterns between 
DLBCLs (de novo and transformed) and LNs (Figure 12). Even though the two tumor 
subtypes showed specific differentially expressed miRNAs in comparison to LNs, most 
of miRNAs were commonly deregulated in both de novo and transformed DLBCLs 
suggesting that the two tumor types may employ partly overlapping regulatory 
pathways. In addition, we identified a classifier of 11 miRNAs that could distinguish 
the de novo from transformed cases. 
 
Given the genetic variation between DLBCLs, we attempted to find deregulated 
miRNAs that could characterize different subtypes among the de novo cases. We first 
identified a set of six miRNAs associated with GCB and non-GCB immunophenotypes. 
Concordant with previous studies, miR-155 and miR-146a were over-expressed in non-
GCB cases (Lawrie et al., 2007; Malumbres et al., 2009; Roehle et al., 2008). However, 
deregulation of the other four miRNAs was not previously reported: discrepancies may 
be due to interpretations of immunohistochemical staining to distinguish GCB and non-
GCB cases, different technical approaches adopted in the studies or the use of cell line 
instead of clinical samples to identify miRNA signatures. Further, we observed an 
inverse correlation between altered miRNAs and expression of Bcl-6 and IRF-4, which 
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are commonly deregulated in DLBCL and have a prognostic impact in this type of 
lymphoma. We also found that over-expression of miR-494 was associated with 
DLBCL cases in advance stages (III-IV) of disease. Even though little is known about 
the function of this miRNA in lymphomas, increased expression of miR-494 and its 
potential role in tumor development has been reported in other cancer types (Arribas et 
al., 2012; Liu et al., 2010; Wang et al., 2010).   
 
 
 
 
 
 
 
Figure 12. The heat maps show unsupervised clustering of miRNA expression 
profiling in LNs and DLBCLs (A) as well as LNs and de novo DLBCLs only (B) or 
LNs and transformed DLBCL only (C). The several distinct cluster may reflect the 
highly heterogeneity that characterize DLBCLs.  
A B C
Normal lymph nodes (LNs)
De novo DLBCLs
Transformed DLBCLs (DLBCL-t)
0.020.00-0.02
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Beside the analysis of global miRNA expression, we investigated miRNA machinery 
deregulation in DLBCL in the attempt to understand the possible role in 
lymphomagenesis. We observed a significant over-expression of TRBP2 in de novo 
DLBCLs as compared to LNs and decreased expression of DROSHA, DICER, TRBP2 
and PACT in transformed DLBCLs v.s. de novo cases. We then demonstrated that 
altered expression of miRNA machinery factors could affect the processing efficiency 
of miR-155 and miR-146a, explaining the observed over-expression of these miRNA in 
de novo DLBCLs (Figure 13). Moreover, we unraveled the tumorigenic potential of 
TRBP2 in DLBCL showing that inhibition of TRBP2 expression in lymphoma cell 
lines could affect both proliferation and apoptosis.  
 
In conclusion, our results underline the importance of miRNAs as molecular markers to 
sub-classify DLBCL tumors. Further, we showed the possible implications of miRNA 
processing factors deregulation in the development of DLBCLs.  
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Histograms show a significant higher miRNA processing efficiency in de 
novo DLBCLs as compared to transformed DLBCLs and LNs (top), while the levels of 
pri-miRNA are similar between groups (bottom). **p<0.01; ***p<0.001.                         
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5 CONCLUDING REMARKS 
 
The miRNA field is in a continuous growth and an increasing number of studies are 
constantly underlining the crucial importance of these small non-coding RNAs in the 
pathogenesis of different tumor types. Despite all the achievements, our knowledge of 
the biological role of these molecules in tumor development and progression is still in 
its infancy. In this thesis work we attempted to improve our understanding of the 
clinical and functional impact of miRNAs in three different cancer types, e.g. 
metastatic melanoma, adrenocortical carcinoma and diffuse large B-cell lymphoma. 
According to our findings we can conclude that: 
 
1. miRNA expression deregulation is a frequent event in different tumor types such as 
metastatic melanoma, adrenocortical carcinoma (ACC) and diffuse large B-cell 
lymphoma (DLBCL) (Papers I, II and IV). In addition, using DLBCL as tumor-
model, we confirmed the potential of miRNAs as molecular biomarkers to classify 
different tumor sub-types (Papers IV). 
 
2. We demonstrated the prognostic value of miRNAs in human cancer, identifying 
miRNA signatures associated with poor prognosis in patients with metastatic 
melanoma and ACC (Papers I and II). In addition, we partly elucidated the functional 
role of miR-483, miR-195 and miR-497 in the pathogenesis of ACC and showed the 
potential involvement of the pro-apoptotic factor PUMA (a target of miR-483-3p) in 
adrenocortical tumors. 
 
3. Beside miRNA expression alteration, we reported deregulation of miRNA 
processing factors in ACC and DLBCL tumors. We also demonstrated that abnormal 
expression levels of miRNA machinery genes can affect miRNA biogenesis. Further, 
we showed that over-expression of TRBP2 was a common event in both ACC and de 
novo DLBCL tumors and we unraveled its potential oncogenic role in the pathogenesis 
of both tumor types. Additionally, we proposed possible regulatory mechanisms (e.g 
copy number variation and miRNA-mediated post-transcriptional regulation) that could 
lead to TRBP2 over-expression in ACC (Papers III and IV). 
 
4. We showed that TRBP2 is a useful predictor of malignancy to reliably discriminate 
adrenocortical carcinomas from adenoma tumors. These findings suggest that TRBP2 
might be used as a novel molecular marker in combination with other tools currently in 
use in clinical practice for management of adrenocortical carcinomas (Paper III). 
Given the role of TRBP2 as oncogene and its prognostic value in ACC, we also 
speculate that deeper understanding of the molecular mechanisms involved in the over-
expression of TRBP2 in ACC may lead to development of new and more targeted 
therapies.  
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